oleclumab (MEDI9447) / AstraZeneca  >>  Phase 2
Welcome,         Profile    Billing    Logout  

21 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oleclumab (MEDI9447) / AstraZeneca
NeoCOAST, NCT03794544 / 2018-002932-26: Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Checkmark From NeoCOAST trial for resectable early stage NSCLC
Apr 2022 - Apr 2022: From NeoCOAST trial for resectable early stage NSCLC
Completed
2
84
Europe, Canada, US
Durvalumab, MEDI4736, Oleclumab, MEDI9447, Monalizumab, IPH2201, Danvatirsen, AZD9150
MedImmune LLC
Resectable, Early-stage, NSCLC
01/21
01/21
NCT04089553: An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Completed
2
59
US
AZD4635, Oleclumab, MEDI9447, Durvalumab, Imfinzi, MEDI4736
AstraZeneca
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
06/21
04/23
NSGO, NCT03267589 / 2017-002805-36: Trial in Patients With Relapsed Ovarian Cancer

Completed
2
25
Europe
Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Nordic Society of Gynaecological Oncology - Clinical Trials Unit, Gynecologic Cancer Intergroup (GCIG), European Network of Gynaecological Oncological Trial Groups (ENGOT)
Ovarian Cancer
10/21
10/21
DOME, NCT04262388: A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation

Withdrawn
2
0
Canada
Durvalumab, IMFINZI, Oleclumab
University Health Network, Toronto, AstraZeneca
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
01/23
01/23
COAST, NCT03822351 / 2018-002931-35: Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Checkmark From COAST trial for NSCLC at ESMO 2021
Sep 2021 - Sep 2021: From COAST trial for NSCLC at ESMO 2021
Checkmark Presentation of data from COAST trial for stage III unresectable NSCLC at ESMO 2021
Sep 2021 - Sep 2021: Presentation of data from COAST trial for stage III unresectable NSCLC at ESMO 2021
Completed
2
188
Europe, Canada, US, RoW
Durvalumab + Oleclumab, Durvalumab (MEDI-4736), Oleclumab (MEDI-9447), Durvalumab, Durvalumab + Monalizumab, Monalizumab (IPH2201)
MedImmune LLC
Stage III Non-small Cell Lung Cancer, Unresectable
07/23
07/23
PIONeeR, NCT03833440: Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

Active, not recruiting
2
114
Europe
Durvalumab (MEDI4736), Monalizumab (IPH2201), Oleclumab (MEDI9447), Ceralasertib (AZD6738), DOCETAXEL, Savolitinib
Assistance Publique Hopitaux De Marseille
Non-small Cell Lung Cancer
10/24
02/25
DOMINATION, NCT04262375: A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION

Withdrawn
2
0
Canada
Durvalumab, IMFINZI, Oleclumab
University Health Network, Toronto, AstraZeneca
Non Small Cell Lung Cancer, Renal Cell Carcinoma
01/24
01/24
Neo-CheckRay, NCT03875573 / 2018-004165-13: Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

Active, not recruiting
2
147
Europe
Durvalumab, MEDI4736, Stereotactic Body Radiotherapy, SBRT, Oleclumab, MEDI9447
Jules Bordet Institute, Institut Curie, AstraZeneca
Luminal B
09/24
09/29
NCT04145193: Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Withdrawn
2
0
NA
Standard of Care - mFOLFOX6, FOLFOX (Oxaliplatin, Folinic acid (leucovorin), Fluorouracil (5-FU)), E1 - mFOLFOX and durvalumab, Durvalumab (MEDI-4736), E2 - mFOLFOX6, durvalumab and oleclumab, Durvalumab (MEDI-4736) + Oleclumab (MEDI-9447), E3 - mFOLFOX6, durvalumab and monalizumab, Durvalumab (MEDI-4736) + Monalizumab (IPH2201)
MedImmune LLC
Microsatellite-stable Colorectal Cancer
03/24
03/24
DOSa, NCT04668300: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Recruiting
2
75
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Oleclumab, Anti-CD73 Monoclonal Antibody MEDI9447, MEDI9447
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma, Recurrent Angiosarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Osteosarcoma, Refractory Dedifferentiated Liposarcoma, Refractory Osteosarcoma
06/24
06/24
HUDSON, NCT03334617 / 2017-002208-28: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Calendar Jan 2024 - Dec 2024: Data from HUDSON trial for NSCLC
Active, not recruiting
2
531
Europe, Canada, US, RoW
Durvalumab, AZD9150, AZD6738, Vistusertib, Olaparib, Oleclumab, trastuzumab deruxtecan, cediranib, AZD6738 (ceralasertib), AZD6738 (ceralasertib) (240 mg or 160 mg), AZD6738 (ceralasertib) 7 days monotherapy
AstraZeneca
Non-Small Cell Lung Cancer
09/24
09/24
NCT04940286: Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Recruiting
2
30
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Oleclumab, Anti-CD73 Monoclonal Antibody MEDI9447, MEDI9447
M.D. Anderson Cancer Center
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
10/25
10/25
DORA, NCT06060405: Durvalumab and Oleclumab in Resectable PDAC

Recruiting
2
22
Canada
Durvalumab, IMFINZI, Oleclumab, MEDI9447
University Health Network, Toronto
Pancreatic Ductal Adenocarcinoma
10/26
10/26
NeoCOAST-2, NCT05061550 / 2021-003369-37: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Data from NeoCOAST-2 trial for early stage, resectable NSCLC
Recruiting
2
490
Europe, Canada, US, RoW
Durvalumab, MEDI4736, IMFINZI, Oleclumab, MEDI9447, Monalizumab, IPH2201, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, MEDI5752
AstraZeneca, Parexel
Non-small Cell Lung Cancer
12/28
12/28
D6070C00005, NCT03611556 / 2018-001028-21: MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Hourglass Jan 2023 - Jun 2023 : Data from trial for pancreatic cancer
Completed
1b/2
213
Europe, US, RoW
Oleclumab, MEDI9447, Durvalumab, MEDI4736, Gemcitabine, Nab-paclitaxel, Oxaliplatin, Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU), Folinic acid, 5-FU
MedImmune LLC
Carcinoma, Metastatic Pancreatic Adenocarcinoma
07/22
07/22
2018-000764-29: A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies with or without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Not yet recruiting
1/2
320
Europe
durvalumab, Oleclumab, Capivasertib, Trastuzumab Deruxtecan, MEDI4736, MEDI9447, AZD5363, DS-8201a, Concentrate for solution for infusion, Tablet, Powder for concentrate for solution for infusion
AstraZeneca AB, AstraZeneca
First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2., Treatment of first line (1L) metastatic triple negative breast cancer (TNBC)., Diseases [C] - Cancer [C04]
 
 
NCT03381274: Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Active, not recruiting
1/2
43
US, RoW
Oleclumab, MEDI9447, Osimertinib, Tagrisso®, AZD4635
MedImmune LLC
Carcinoma, Non-Small-Cell Lung
05/21
07/25
2019-000974-44: A Study of Novel Oncology Therapies in Combination with FOLFOX and Bevacizumab in Metastatic Microsatellite-Stable Colorectal Cancer Estudio de tratamientos oncológicos novedosos en combinación con FOLFOX y bevacizumab en cáncer colorrectal con estabilidad de microsatélites metastásico

Not yet recruiting
1/2
114
Europe
durvalumab, oleclumab, MEDI4736, MEDI9447, Concentrate for solution for infusion
AstraZeneca AB, AstraZeneca AB
Metastatic Microsatellite-Stable Colorectal Cancer Cáncer colorrectal con microsatélites estables metastásico, Metastatic Colorectal Cancer Cáncer colorrectal metastásico, Diseases [C] - Cancer [C04]
 
 
COLUMBIA 1, NCT04068610: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Terminated
1/2
61
Europe, Canada, US, RoW
Durvalumab, MEDI4736, Oleclumab, MEDI9447, FOLFOX, Bevacizumab
MedImmune LLC
Metastatic Microsatellite-stable Colorectal Cancer
10/22
10/22
SYNERGY, NCT03616886 / 2017-004651-23: Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

Active, not recruiting
1/2
129
Europe
Paclitaxel, Carboplatin, MEDI4736, Durvalumab, MEDI9447, Oleclumab
Jules Bordet Institute, AstraZeneca
Triple Negative Breast Cancer
08/24
04/25
BEGONIA, NCT03742102: A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Checkmark Data from arm-6 of BEGONIA trial in combination with durvalumab for locally advanced or metastatic stage IV TNBC at SABCS 2022
Dec 2022 - Dec 2022: Data from arm-6 of BEGONIA trial in combination with durvalumab for locally advanced or metastatic stage IV TNBC at SABCS 2022
Checkmark Data from arm-7 of BEGONIA trial in combination with durvalumab for TNBC at SABCS 2022
Dec 2022 - Dec 2022: Data from arm-7 of BEGONIA trial in combination with durvalumab for TNBC at SABCS 2022
Checkmark Presentation of results from P1b/2 BEGONIA trial for metastatic TNBC at SABCS 2022
More
Recruiting
1/2
240
Europe, Canada, US, RoW
Durvalumab, MEDI4736, Capivasertib, AZD5363, Oleclumab, MEDI9447, Paclitaxel, Trastuzumab deruxtecan, DS-8201a, Datopotamab deruxtecan, Dato-DXd; DS-1062a
AstraZeneca
Triple Negative Breast Neoplasms
11/24
11/24

Download Options